Literature DB >> 25614007

Therapeutic resistance: paradox breaking.

M Teresa Villanueva.   

Abstract

Year:  2015        PMID: 25614007     DOI: 10.1038/nrc3900

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


× No keyword cloud information.
  2 in total

1.  Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction.

Authors:  Gatien Moriceau; Willy Hugo; Aayoung Hong; Hubing Shi; Xiangju Kong; Clarissa C Yu; Richard C Koya; Ahmed A Samatar; Negar Khanlou; Jonathan Braun; Kathleen Ruchalski; Heike Seifert; James Larkin; Kimberly B Dahlman; Douglas B Johnson; Alain Algazi; Jeffrey A Sosman; Antoni Ribas; Roger S Lo
Journal:  Cancer Cell       Date:  2015-01-15       Impact factor: 31.743

2.  Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma.

Authors:  Maria Romina Girotti; Filipa Lopes; Natasha Preece; Dan Niculescu-Duvaz; Alfonso Zambon; Lawrence Davies; Steven Whittaker; Grazia Saturno; Amaya Viros; Malin Pedersen; Bart M J M Suijkerbuijk; Delphine Menard; Robert McLeary; Louise Johnson; Laura Fish; Sarah Ejiama; Berta Sanchez-Laorden; Juliane Hohloch; Neil Carragher; Kenneth Macleod; Garry Ashton; Anna A Marusiak; Alberto Fusi; John Brognard; Margaret Frame; Paul Lorigan; Richard Marais; Caroline Springer
Journal:  Cancer Cell       Date:  2014-12-11       Impact factor: 31.743

  2 in total
  4 in total

1.  Acetylsalicylic Acid Governs the Effect of Sorafenib in RAS-Mutant Cancers.

Authors:  Dinoop Ravindran Menon; Sabrina Hammerlindl; Heinz Hammerlindl; Abdullah Al Emran; Joachim Torrano; Katrin Sproesser; Divya Thakkar; Min Xiao; Victoria G Atkinson; Brian Gabrielli; Nikolas K Haass; Meenhard Herlyn; Clemens Krepler; Helmut Schaider
Journal:  Clin Cancer Res       Date:  2017-12-01       Impact factor: 12.531

2.  Pin1-FOXM1 inhibitors: a potential therapeutic for metastatic melanoma?

Authors:  Peter Lj de Keizer
Journal:  Melanoma Manag       Date:  2016-08-31

3.  Nanotechnological approaches for counteracting multidrug resistance in cancer.

Authors:  Chiara Martinelli; Marco Biglietti
Journal:  Cancer Drug Resist       Date:  2020-10-12

4.  Nanotechnology-based combination therapy for overcoming multidrug-resistant cancer.

Authors:  Meng Zhang; Ergang Liu; Yanna Cui; Yongzhuo Huang
Journal:  Cancer Biol Med       Date:  2017-08       Impact factor: 4.248

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.